There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SPR /BLI analytical service

SPR /BLI analytical service

Biomolecular interaction analysis is used increasingly in drug development to kinetically characterize binding events of relevant components, including drugs and targets, antibodies and antigens or any pair of interacting molecules including protein-protein, protein-nucleic acid and protein-lipid interactions. Based on the Biacore T200/8K platform and ForteBio Octet platform, ACROBiosystems provides SPR /BLI analytical services to our valued customers. The SPR/BLI analytical services include antibody screening, antibody pairing/group, kinetic analysis, and interaction measurement.

Surface Plasmon Resonance (SPR) service
Biacore 8K
Biacore T200
Surface Plasmon Resonance (SPR) technology is the leader and standard in the field of biomolecular interactions. SPR technology can provide unique insights to reveal the interaction between biomolecules, and help scientists understand the function of biomolecules.
Biolayer Interferometry (BLI) service
ForteBio Octet 96e
Biolayer Interferometry (BLI) technology can implement the quantitative and qualitative analysis of intermolecular affinity with the advantages of high sensitivity, high throughput and low sample volume.
ACROBiosystems can provide custom solutions to meet your following needs!
Fast and reliable services-Supporting full-cycle of drug development

Promotion period: April.1-July.31,2021
ACRO proteins supplied free
Only provide samples to get service completed

Case Study

Antibody binding with target protein

Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

BsAb binding with Fc receptor protein

The total solution for antibody and Fc receptor affinity testing

All Fc receptor proteins needed are free of charge
Only provide analytes, then get the full service


Case study
Antibody screening/characterization/ bioequivalence evaluation

Anti- BCMA antibodies (Mouse IgG1) captured on CM5 chip via anti-Mouse IgG antibodies, can bind to Human BCMA Protein, His Tag (Cat. No. BCA-H522y) as determined using a SPR (Biacore T200).

Opdivo (Nivolumab) loaded on Protein A Biosensor, can bind to Human PD-1, His Tag (HPLC-verified) (Cat. No. PD1-H5221) with an affinity constant of 5.09 nM as determined using a BLI assay (ForteBio Octet Red96e).

Fc receptor protein affinity testing
Herceptin &Human Fc gamma RI / CD64(SPR analytical service)

Human CD64, His Tag (SPR & BLI verified) immobilized on CM5 Chip via an anti-His antibody, can bind to Herceptin with an affinity constant of 5.45 nM as determined in a SPR assay (Biacore T200) (QC tested).

Herceptin &Human Fc gamma RI / CD64(BLI analytical service)

Human CD64, His Tag (SPR & BLI verified) loaded on HIS1K Biosensor, can bind to Herceptin with an affinity constant of 13 nM as determined in a BLI assay (ForteBio Octet Red96e) (Routinely tested).

Large molecules affinity testing

Trastuzumab can bind to C1q with an affinity constant of 3.24 nM as determined in BLI assay (ForteBio Octet Red96e).

Small molecule affinity testing

SARS-CoV-2 3CL-Mpro, His Tag immobilized on CM5 Chip can bind to Dipyridamole with an affinity constant of 65.1 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

Comprehensive protein products

Using in house protein products, such as Fc receptor proteins, immunological checkpoint proteins, biotin-labeled proteins, etc. can guarantee the assay performance.

Professional R&D technical team

We have a professional team with abundant SPR experience to develop and optimize the SPR assays.

Responsive project operation team

You will hear back from our established project management team within one day. We provide frequent and detailed updates and follow-ups to make sure you keep track of your projects.

Still have questions?

This web search service is supported by Google Inc.